Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Gastroesophageal Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Gastric Cancer (777
)
Gastroesophageal Junction Adenocarcinoma (183
)
Gastric Adenocarcinoma (40
)
Gastric Cancer (777
)
Gastroesophageal Junction Adenocarcinoma (183
)
Gastric Adenocarcinoma (40
)
›
Associations
(41)
News
Trials
Search handles
@AndresC27622123
@ArndtVogel
@DrR_DUNNE
@Dr_R_Kurzrock
@GillSharlene
@JoeChaoMD
@KellyBorgesAra2
@KlempnerSam
@KoheiShitara
@LizzySmyth1
@MyriamChalabi
@PamelaKunzMD
@RussellPetty19
@RyanMoyMDPhD
@Sarbaji85064063
@YJanjigianMD
@benweinbergmd
@cancerassassin1
@dr_yakupergun
@drjasonstarr
@guildsman
@kimtruss
@loconte
@marklewismd
Search handles
@AndresC27622123
@ArndtVogel
@DrR_DUNNE
@Dr_R_Kurzrock
@GillSharlene
@JoeChaoMD
@KellyBorgesAra2
@KlempnerSam
@KoheiShitara
@LizzySmyth1
@MyriamChalabi
@PamelaKunzMD
@RussellPetty19
@RyanMoyMDPhD
@Sarbaji85064063
@YJanjigianMD
@benweinbergmd
@cancerassassin1
@dr_yakupergun
@drjasonstarr
@guildsman
@kimtruss
@loconte
@marklewismd
Filter by
Latest
9ms
Interested in the latest in #CARTcelltherapy and treatment of HER2+ #esophagogastriccancer and KRAS-G12 C-mutant #NSCLC? You'll find brief summaries of work by @MSKCancerCenter's @jaeparkmd, @YJanjigianMD, @SteveMaronMD, @rohit_thum, + @KCArbourMD here. https://t.co/GDzcsZ7csG (@MSK_DeptOfMed)
9 months ago
CAR T-Cell Therapy
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
10ms
EGFR Inhibition in EGFR–Amplified Gastroesophageal Cancer 60 pts ORR All pts➡️43% ChT plus EGFRi➡️57% mPFS All pts➡️4.6 mo ChT plus EGFRi➡️6.0 mo First line➡️6.9 mo 📌Well-selected patients with EGFR-amplified GEA derive significant benefit from EGFRi @JCO_ASCO… https://t.co/CJfrsAqzMH (@dr_yakupergun)
10 months ago
Clinical
|
EGFR amplification
10ms
Check out this on demand webinar on gastroesophageal cancer provided by experts @YJanjigianMD @KlempnerSam and @LizzySmyth1 Now available as an accredited e-learning https://t.co/srAajgJZtN #MedEd (@giconnectInfo)
10 months ago
10ms
Out in @CCR_AACR. @SteveMaronMD @ILSONDavid @JeeyunM @YJanjigianMD and others. Determinants of survival in HER2+ metastatic esophagogastric cancer https://t.co/1JnQbb0krS (@KlempnerSam)
10 months ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
10ms
Outstanding gastroesophageal cancer session at #WCGIC2023 and excellent abstract presentations from colleagues of our group 👏🏻@FilippoPietran4 @LizzySmyth1 @KoheiShitara #giovannirandon @Mom_enji (@margheambro1)
10 months ago
10ms
Fantastic talk by @FilippoPietran4 on MSI-H/dMMR esophagogastric cancers. I encourage everybody to rewatch! #WCGIC2023 @myESMO (@MyriamChalabi)
10 months ago
MSI (Microsatellite instability)
|
MSI-H/dMMR
10ms
Dr. Manish Shah (@mdmanishshah) is presenting on managing HER2-positive metastatic #GastricCancer/#GastroesophagealCancer @NACECME’s #ConversationsInOncology virtual conference this weekend. Learn more and register to earn #CME credit: https://t.co/3RCKzVpEE2 (@WCMGIcancer)
10 months ago
Oncolytic virus • CME • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
10ms
Keynote 585 of perioperative pembrolizumab for #gastriccancer did not meet EFS endpoint despite higher pCR. Unfortunate but an important global study for localized gastroesophageal cancer. Stay tuned for full results @OncoAlert @myESMO @ASCO https://t.co/yKPzIycaKO (@KoheiShitara)
10 months ago
Keytruda (pembrolizumab)
11ms
Excited to finally share that Keynote 811 survival data in first line HER2+ gastroesophageal cancer will be presented at @myESMO @MSKCancerCenter @MSK_DeptOfMed https://t.co/uxKYFNMNMT (@YJanjigianMD)
11 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
11ms
🔥Great talk🔥Dare to dream🚀….@FilippoPietran4 discusses the non -operative management of gastroesophageal cancer with immunotherapy at #OF23 Precise patient selection for immunotherapy at all stages is crucial . @OncologyForum (@RussellPetty19)
11 months ago
Clinical
11ms
Dr. Manish Shah presented phase II study of teiomelysin + pembro in gastroesophageal cancer. @mdmanishshah @WCMGIcancer #ASCO23 (@christinemphmd)
11 months ago
P2 data
|
Keytruda (pembrolizumab)
11ms
#ASCO23 | Hall A | Monday 8am CT Circulating Tumor DNA as a Marker of Recurrence Risk in Locoregional Esophagogastric Cancers With Pathologic Complete Response @KlempnerSam ➡️ https://t.co/I4j2RKV3WG @ASCO #MGCCatASCO23 (@MGHCancerCenter)
11 months ago
Clinical • Circulating tumor DNA
11ms
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. @UPMCnews @UPMCHillmanCC @AnwaarSaeed3 & colleagues @CellRepMed #ASCO23 https://t.co/Px2ISHF1ec (@CellPressNews)
11 months ago
Metastases
|
Imfinzi (durvalumab) • Cabometyx (cabozantinib tablet)
12ms
From @medpagetoday: Dr. Manish A. Shah (@mdmanishshah), an @WCMEnglanderIPM member on "A new @ASCO guideline offers recommendations on the use of #immunotherapy and targeted therapy for advanced #gastroesophageal cancer." https://t.co/lTsTm6gItN (@WCMEnglanderIPM)
12 months ago
Metastases
12ms
New accredited e-learning on gastroesophageal cancer with top experts @YJanjigianMD @KlempnerSam and @LizzySmyth1 Access the video, slides and e-learning here https://t.co/srAajgJZtN #meded #oncology (@giconnectInfo)
12 months ago
Video
12ms
Trial data for esophageal & gastroesophageal cancers were highlighted during #ASCOGI23, showing significant advances & promise for this patient population. #gicsm | @CathyEngMD @VUMC_Cancer @SteveMaronMD @MSKCancerCenter https://t.co/p4Cnlfx0PK (@TargetedOnc)
12 months ago
Clinical
12ms
#HER2 Targeting in #EsophagogastricCancer: Redefining the Landscape and Breaking Barriers: https://t.co/rB57AsXxJX #GICSM Review by @Sam_Cytryn & @YJanjigianMD of @MSKCancerCenter (@JNCCN)
12 months ago
Review
|
HER-2 (Human epidermal growth factor receptor 2)
12ms
Our latest.. lead by @YJanjigianMD... Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using 89Zr-Trastuzumab PET: A Pilot Study https://t.co/1a69lRbAnE (@LewisLabMSKCC)
12 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab)
1year
🔥HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape & Breaking Barriers https://t.co/BlU3H9WjT5 @JNCCN 👏great review 👉rapidly changing landscape - from trastuzumab + IO to ADCs, vaccines & CARs - from peri-OP to treatment beyond progression @myESMO @OncoAlert… https://t.co/osdQZ2P5ci (@ArndtVogel)
1 year ago
Clinical • Review
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab)
1year
Great news! Our new paper: The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma is available online. Check it out here: https://t.co/NEuLKDPgsP #oncology #HER2positive #gastroesophagealcancer @_SEOM (@kimtruss)
1 year ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
1year
🔥T-DXd in HER2-low #esophagogastriccancer @JCO_ASCO https://t.co/92F6dcQ6fO ✅🇯🇵phs-II, 45 pts; C1 IHC 2+ vs C1+ 👉ORR: 26% vs 10% 👉mOS: 7.8 vs 8.5mo 🧐Interesting signal🚦in Her2 2+ ,🎯-naive pts.... is there a place of Her2-low in gastric cancer? @myESMO @OncoAlert (@ArndtVogel)
1 year ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
1year
Gastrointestinal & Genitourinary Masterclass January 27-28, 2023 DAY 2 Session 3: Gastroesophageal cancer / Hpb UPDATE ON THE MANAGEMENT OF HER-2+ ADVANCED GE CANCER Dr. Ali Al Zahrani Moderators Dr. Mohammed Al Garni @algarni_moh Dr. Kanan AlShammari @Dr_Kanaan07 (@Oncology_Events)
1 year ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
over1year
🔥Tislelizumab + CTx vs CTx as 1L for #gastroesophageal cancer @ ASCO-GI 2023 ✅RATIONALE-305 Phs-III, 549 pts PDL1+ (PD-L1>5%) 👉mOS 17.6 vs 12.6 mo 👉mPFS 7.2 vs 5.9 mo 👉ORR 50.4 vs 43% 👉Additional support for IO in PD-L1+ gastric cancer, ITT awaited @myESMO @OncoAlert (@ArndtVogel)
over 1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
Tevimbra (tislelizumab)
over1year
🎉 Ecstatic that @AliAlqahtaniMD was awarded an @ASCO @ConquerCancerFd Merit Award for his oral presentation #GI23 on HER2-high vs. low #gastroesophagealcancer from an analysis of the @carisls database ➡️ TWEETORIAL TIME!📢📢@RueschCenter @LombardiCancer @GUMedicine @gumedcenter (@benweinbergmd)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2-H
over1year
HER2-low vs high: a concept that steps up in the GI onc lexicon today with this oral presentation by Dr. Alqahtani, fellow at @LombardiCancer, from Caris GI POA group. Comparative analysis of molecular profile and tumor immune microenvironment in gastroesophageal cancers. #GI23 (@cancerassassin1)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
over1year
RATIONALE-305 finds Tislelizumab (anti-PD1 ab) plus chemo is superior (HR 0.74 for OS) to chemo alone in Her2 negative #gastriccancer Another new frontline option in the ever-evolving gastroesophageal cancer landscape #GI23 (@DrR_DUNNE)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Tevimbra (tislelizumab)
over1year
We presented our data on the prevalence, genetic and immune landscape of ERBB2/ERBB3 altered gastroesophageal cancers. Thanks to @TempusLabs and @mdmanishshah for this collaboration! @ASCO @RoswellPark #GI23 #CancerResearch (@Sarbaji85064063)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
over1year
Positive study of zolbetuximab (claudin 18.2 Ab) plus FOLFOX for 1st line treatment in Claudin expressing stage IV gastroesophageal cancer - Shitara et al SPOTLIGHT trial LBA292 #gi23 (@loconte)
over 1 year ago
Metastases
|
CLDN18 (Claudin 18)
|
5-fluorouracil • leucovorin calcium • Vyloy (zolbetuximab)
over1year
Presenting my poster now on CCNE1-amplified esophagogastric cancer. Collaboration with Caris POA #GI23 (@RyanMoyMDPhD)
over 1 year ago
CCNE1 (Cyclin E1)
|
CCNE1 amplification
over1year
🎉Ecstatic that our intrepid fellow @AliAlqahtaniMD was awarded an @ASCO @ConquerCancerFd Merit Award for his oral presentation #GI23 on HER2 high vs. low #gastroesophagealcancer using the @carisls database - tweetorial time!!! 📢 @RueschCenter @LombardiCancer @GUMedicine (@benweinbergmd)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2-H
over1year
🔥Neoadjuvant Nivo/Ipi & adjuvant Nivo in MSI gastroesophagogastric cancer @JCO_ASCO https://t.co/XRfaMe5X0Z ✅NEONIPIGA phs-II 32 pts 👉3cCR, 59% pCR, 79% TRG1/2 👉29 surgery -> no relapse 🧐pCR 38% with FLOT 🤔IO in MSI = opt for watch & wait for some pts? @myESMO @OncoAlert (@ArndtVogel)
over 1 year ago
Clinical • Surgery
|
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
over1year
🔥ctDNA to predict risk of recurrence in esophagogastric cancer 🔥 @JCOPO_ASCO https://t.co/NmGrUjVE2n ✅🇺🇸RWD 295pts 🔎Signatera/16 pt specific SNVs -> ctDNA pos.: 👉pre-OP: 96% 👉post-OP: 23% -> strongly associated with RFS 👏Helpful for risk stratification @myESMO @OncoAlert ()
over 1 year ago
Circulating tumor DNA
|
Signatera™
over1year
We favor multidisciplinary review and usually surgery upfront or consideration for a trial for MSI-H perioperative therapy for gastroesophageal malignancies. (@guildsman)
over 1 year ago
Review
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
over1year
Trastuzumab deruxtecan is a powerful 💥 drug in HER2+ve oesophagogastric cancer. Recent 2L EMA approval based on DESTINY Gastric 02 results is great news for patients ✅ ❓can we replicate TdXD activity in HER2 low GC as seen in HER2 low mBC? Promising ORR but need ⬆️ numbers. (@LizzySmyth1)
over 1 year ago
Clinical • European regulatory
|
HER-2 (Human epidermal growth factor receptor 2)
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
over1year
Happy to share our contribution to #ASCODailyNews @ASCO @BCCancer ➡️ topical Q for dMMR GI cancers & potential for organ preservation 👇IO as Neoadjuvant Therapy for dMMR/MSI-H Esophagogastric Cancer: Could This Be a New SOC? https://t.co/6jbA3HHSwp (@GillSharlene)
over 1 year ago
Clinical
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
almost2years
PD-L1 Test Debated in Gastroesophageal Cancer Immunotherapy https://t.co/qR8LAZSKNX via @medscape (@Spanishcountry)
almost 2 years ago
PD-L1 (Programmed death ligand 1)
2years
🎊We share with you #Review "Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers" in #mdpiDiseases, 👥by Dr. Jun Gong et al. @jgong15 Enjoy reading 🔗https://t.co/UmNrywAHvL Keywords: #gastroesophageal #cancer #trastuzumab #HER2 (@Diseases_MDPI)
2 years ago
Review
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
Herceptin (trastuzumab)
2years
Recent single institution study by @GIcancerDoc @MayoClinic had suggested increased prevalence of BRCA1/2 mutations in gastroesophageal cancers. Now cholangiocarcinoma should be added to list of universal germline testing. @JavleMilind @rachnatshroff @pashtoonkasi @MPishvaian (@Aiims1742)
2 years ago
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation
2years
31) Welcome back!! We are highlighting new data from @ASCO #GI22 on gastro-esophageal cancers & HER2-targeted therapies. Our expert author is @SKamath_MD from @ClevelandClinic. The topics are gastro-esophageal cancers & HER2-targeted therapies. (@onc_ce)
2 years ago
HER-2 (Human epidermal growth factor receptor 2)
2years
2) Now we are covering @ASCO #GI22, which just wrapped up this past week --only the most current updates for OUR followers! Our expert author is Dr. Suneel Kamath (@SKamath_MD) from @ClevelandClinic in Ohio. The topics are gastro-esophageal cancers & HER2-targeted therapies. (@onc_ce)
2 years ago
HER-2 (Human epidermal growth factor receptor 2)
over2years
Agree with @ajscott40 re: limitations of PDL1 testing in esophagogastric cancers in 2022 - why is it so complicated? #GI22 (@GillSharlene)
over 2 years ago
PD-L1 (Programmed death ligand 1)
over2years
Is PDL1 expression before IO therapy in esophagogastric cancers? Great debate question! @FlorianLordick now debating for Yes Health Canada approval also independent of biomarker🇨🇦 🤔...👍for adeno...👎for SCC #GI22 (@GillSharlene)
over 2 years ago
Canadian regulatory • Clinical • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login